Meta Pixel

News and Announcements

Dr Antony Rapisarda of OrthoDx™

  • Published December 06, 2022 6:56AM UTC
  • Publisher Maan Perez
  • Categories Executive Interviews

OrthoDx™ is a privately held company based out of Sydney, Australia, focused on the development and commercialization of novel genomic biomarkers for use in the diagnosis of joint pain. The primary function of the first genomic signature for clinical use is to aid surgeons and physicians to differentiate between infection-negative and infection-positive synovial joint inflammation in adults. 

Watch this interview with CEO Dr. Antony Rapisarda as he discusses SynvIchor™, their biomarker technology and the company’s current and future milestones.

Capital Insights
The Great Life Science Reset: Why the “Sick Care” Model is Failing

The data reveals a significant transition: the end of the traditional sick care model and the rise of a proactive healthcare ecosystem. Learn how smart money is utilising AI to cut drug discovery times in half, transform diagnostics to detect complex diseases in days, and create efficiencies to scale the healthcare system without a proportional increase in costs.

Capital Insights
Australia’s A$4 Trillion Generational Pivot

Australia’s wealth management landscape is undergoing a dramatic transformation. For decades, family offices operated quietly during the “Great Moderation”, an era characterised by low volatility, cheap capital, and global economic synchronisation. Today, that stability has given way to fiscal uncertainty, geopolitical tensions, and intensifying regulatory scrutiny. Yet amid this global turbulence, Australia has emerged as […]

Join over 45,000+ sophisticated investors

Join Now